medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 4

<< Back Next >>

Ann Hepatol 2014; 13 (4)

Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis

Jianyong L, Jinjing Z, Wentao W, Lunan Y, Qiao Z, Bo L, Tianfu W, Minqing X, Jiaying Y, Yongang W

Language: English
References: 33
Page: 399-402
PDF size: 127.39 Kb.


ABSTRACT

Background and aim. The effect of preoperative transcatheter arterial chemoembolization (TACE) on the short- and long-term outcome of resectable hepatocellular carcinoma (HCC) is controversial. We conducted a retrospective evaluation of this aspect using data from our center. Material and methods. A total of 656 consecutive patients who underwent curative resection of HCC were divided into two groups based on the preoperative TACE: the liver resection (LR) group (405 cases) and the TACE-LR group (183 cases). Overall and disease-free survival curves were constructed using the Kaplan-Meier method and compared with the log-rank test. The significance of differences in survival was tested using a log-rank test. Univariate and multivariate analyses were used to identify the factors that best predicted overall survival or tumorfree survival. Results. Although the cost of LR showed no difference between groups, the overall cost was significantly higher in the combined group than in the LR group (P ‹ 0.001). The complication rate after resection was also comparable between the two groups. In regard to long-term outcome, the 1-, 3-, and 5-year overall survival rates were 83.7, 68.9 and 57.5%, respectively, after direct liver resection and 80.9, 65.0 and 54.1%, respectively, after combined TACE and resection (P = 0.739). The 1-, 3-, and 5-year recurrence- free survival rates were also comparable between two groups (P = 0.205). Both univariate analysis and multivariate analysis showed that macro-vascular invasion was the factor that best predicted overall survival or tumor-free survival rate. Conclusion. Preoperative TACE has comparable intraoperative and short-term outcomes but more overall cost due to repeated TACE, and the procedure did not significantly improve the overall or tumor-free survival rate. Preoperative TACE should not, therefore, be recommended as a routine procedure before resection for resectable HCCs particularly in cases due to underlying hepatitis B virus (HBV).


REFERENCES

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

  2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62: 394-9.

  3. Seehofer D, Schoning W, Neuhaus P. Deceased donor liver transplantation. Chiurg 2013; 84: 391-7.

  4. Lei J, Yan L, Wang W. Donor safety in living donor liver transplantation: a single-center analysis of 300 case. PloS One 2013; 8: e61769.

  5. Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, Wu Z. A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol 2013; 28: 793-800.

  6. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, et al. Reevalulation of prognostic factors for survival after liver resection in patients with hepatocellular cacinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.

  7. Lei J, Yan L. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg 2012; 16: 2120-5.

  8. Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg 2007; 31: 2370-7.

  9. Sugo H, Futagawa S, Beppu T, Fukasawa M, Kojima K. Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg 2003; 27: 1295-9.

  10. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopatholocial study of 84 resected cases. Cancer 1994; 73: 2259-67.

  11. Majino PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, et al. Influence of preoperative transarterial lipiodol chemembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.

  12. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, et al. A preospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249: 195-202.

  13. Wang X, Li J, Peng Y, Dai Y, Xu W. Influence of preoperative transarterial chemoembolization on the prognosis for patients with resectable hepatocellular carcinoma: a meta-analysis of randomized trials. Hepatogastroenterology 2011; 58: 869-74.

  14. Uchida M, Kohno H, Kubota H, Hayashi T, Yamanoi A, Kimoto T, Ono T, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20: 326-31.

  15. Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M. Preoperative transcatheter arterial cemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32: 773-9.

  16. Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc 2012; 111: 510-5.

  17. Zhou Y, Zhang X, Wu L, Ye F, Su X, Shi L, Li B. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol 2013; 19: 51.

  18. Lu CD, Peng SY, Jiang XC, Chiba Y, Tanigawa N. Preoperative transcatheter arterial chemoembolization and prognosis of patients with heaptocellular carcinomas: retrospective analysis of 120 cases. World J Surg 1999; 23: 293-300.

  19. Ochiai T, Sonoyama T, Hironaka T, Yamagishi H. Hepatoectomy with chemoembolization for treatment of hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 750-5.

  20. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005; 103: 299-306.

  21. Bonfil RD, Bustuabad OD, Ruggiero RA, Meiss RP, Pasqualini CD. Tumor necrosis can facilitate the appearance of metastases. Clin Exp Metastasis 1998; 6: 121-9.

  22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.

  23. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  24. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.

  25. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19-25.

  26. Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, et al. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol 2010; 16: 383-8.

  27. Huang YS, Chiang JH, Wu JC, Chang FY, Lee SD. Risk of hepatic failure after transarterial chemoembolizaiton for hepatocellular carcinoma: predictive value of the monoethyglycinexylidide test. Am J Gastroenterol 2002; 97: 1223-7.

  28. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A preospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747-52.

  29. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249: 195-202.

  30. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, Peng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-6.

  31. Yamasaki S, Hasegawa H, Kunoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, et al. A prospective randomized trail of the preventive effect of pre-operative transcatheter arterial embolization against recurrence pf hepatocellular carcinoma. Jpn J Cnacer Res 1996; 87: 206-11.

  32. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.

  33. Chua TC, Saxena A, Chu F, Morris DL. Hepatic resection for transplantable hepatocelllular carcinoma for patients within Milan and UCSF criteria. Am J Clin Oncol 2012; 35: 141-5.




2020     |     www.medigraphic.com